Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Inogen Inc . (NASDAQ:INGN) CEO and President Kevin Raymond (NSE:RYMD) Merrill recently made notable transactions involving the company’s stock. On March 3, Merrill acquired 11,709 shares of Inogen common stock in a purchase valued at approximately $100,245, with the price per share averaging $8.5614. The stock, currently trading at $8.03, has declined about 16% in the past week. According to InvestingPro analysis, the stock appears oversold and is trading below its Fair Value.
Additionally, earlier transactions on March 1 saw Merrill acquiring shares through various awards and plans. These included 1,500 shares at $8.33 each through the company’s 2014 Employee Stock Purchase Plan and 28,333 shares acquired at no cost through the exercise of restricted stock units, with a total transaction value of $12,495.
Furthermore, Merrill disposed of 39,797 shares to cover tax liabilities related to vested restricted stock units, with these transactions valued at $331,509 at a price of $8.33 per share. These activities reflect Merrill’s ongoing engagement with Inogen’s stock, aligning with both performance-based incentives and strategic stock purchases.
In other recent news, Inogen Inc. reported a significant earnings beat for the fourth quarter of 2024, posting an earnings per share (EPS) of -$0.41, which exceeded the forecast of -$0.61. The company also achieved revenues of $80.08 million, surpassing the predicted $73.9 million. Inogen’s full-year revenue reached $335.7 million, marking a 6.4% increase from the previous year. The company demonstrated strong growth in its business-to-business channels, both domestically and internationally, although Direct-to-Consumer sales saw a decline. Inogen’s gross margin improved to 46.1% for the full year, up from the previous year. Additionally, Inogen announced a collaboration with UL Medical (TASE:BLWV), which includes a $27 million investment from UL, representing a 9.9% ownership stake. Analysts from firms like William Blair and JPMorgan have shown interest in Inogen’s future strategies, particularly concerning its collaboration with UL and the introduction of new products like the Semiox device.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.